St. Louis, Missouri – August 15, 2008 – The Munich Leukemia Laboratory (MLL) has purchased Partek® Genomics SuiteTM (Partek GS) software Partek Incorporated announced today.

Researchers at MLL will use Partek GS to analyze SNP data from research studies focused in Leukemia. Partek GS can analyze expression, digital gene expression, ChIP-seq/ChIP-chip, exon/alternative splicing, SNP genotyping, and next generation sequencing data. In addition, data can be seamlessly imported from a variety of file formats.

Partek Incorporated is a leading provider of statistical analysis and interactive data visualization software for the scientific research community. Partek software enables researchers to quickly identify and quantify patterns in data, including data resulting from genomic and proteomic studies, high-throughput screening campaigns, and computer aided drug design.

Press Release: 
Story Type: